{
    "clinical_study": {
        "@rank": "95717", 
        "arm_group": [
            {
                "arm_group_label": "ISIS-SMNRx Dose level 1", 
                "arm_group_type": "Experimental", 
                "description": "Administered three times by intrathecal injection"
            }, 
            {
                "arm_group_label": "ISIS-SMNRx:  Dose level 2", 
                "arm_group_type": "Experimental", 
                "description": "Administered three times by intrathecal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the safety, tolerability, and pharmacokinetics of multiple doses of\n      ISIS-SMNRx administered into the spinal fluid three times over the duration of the trial, in\n      patients with Infantile-Onset Spinal Muscular Atrophy."
        }, 
        "brief_title": "A Study to Assess the Safety and Pharmacokinetics of ISIS SMNRx in Infants With Spinal Muscular Atrophy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Muscular Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will test the safety, tolerability, and pharmacokinetics of multiple doses of\n      ISIS-SMNRx administered into the spinal fluid three times over the duration of the trial, in\n      patients with Infantile-Onset Spinal Muscular Atrophy. Two dose levels will be evaluated\n      sequentially. The lowest dose level will be studied in a cohort of 4 patients, and the\n      highest dose level will be studied in a cohort of 4-16 patients.  All patients will receive\n      active drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genetic documentation of 5q SMA (homozygous gene deletion or mutation)\n\n          -  Onset of clinical signs and symptoms consistent with SMA at \u2265 21 days and <6 months\n             (180 days) of age\n\n          -  At study entry, receiving adequate nutrition and hydration (with or without\n             gastrostomy), in the opinion of the Site Investigator\n\n          -  Body weight >5th percentile for age using CDC guidelines\n\n          -  Medical care meets and is expected to continue to meet guidelines set out in the\n             Consensus Statement for Standard of Care in SMA (Wang et al. 2007), in the opinion of\n             the Site Investigator\n\n          -  Gestational age of 35 to 42 weeks and gestation body weight \u22652 kg\n\n          -  Reside within approximately 9 hours ground-travel distance from a participating study\n             center for the duration of the study. Residence >2 hours ground-travel distance from\n             a study center must obtain clearance from the Site Investigator and the study Medical\n             Monitor\n\n          -  Able to complete all study procedures, measurements and visits and parent or\n             guardian/subject has adequately supportive psychosocial circumstances, in the opinion\n             of the Site Investigator\n\n        Exclusion Criteria:\n\n          -  Hypoxemia (O2 saturation awake <96% or O2 saturation asleep <96%, without ventilation\n             support)\n\n          -  Presence of an untreated or inadequately treated active infection requiring systemic\n             antiviral or antimicrobial therapy at any time during the screening period\n\n          -  History of brain or spinal cord disease that would interfere with the LP procedures,\n             CSF circulation, or safety assessments\n\n          -  Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter\n\n          -  History of bacterial meningitis\n\n          -  Clinically significant abnormalities in hematology or clinical chemistry parameters,\n             as assessed by the Site Investigator, at screening that would render the subject\n             unsuitable for inclusion\n\n          -  Treatment with another investigational drug (e.g., albuterol, riluzole, carnitine,\n             creatine, sodium phenylbutyrate, salbutamol, valproate, hydroxyurea etc), biological\n             agent, or device within 90 days prior to enrollment or anytime during the study.  Any\n             history of gene therapy or cell transplantation\n\n          -  The subject's parent(s) or legal guardian(s) is unable to understand the nature,\n             scope, and possible consequences of the study, or does not agree to comply with the\n             protocol defined schedule of assessments\n\n          -  Ongoing medical condition that according to the Site Investigator would interfere\n             with the conduct and assessments of the study.  Examples are medical disability other\n             than SMA that would interfere with the assessment of safety or would compromise the\n             ability of the subject to undergo study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "210 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839656", 
            "org_study_id": "ISIS 396443-CS3A"
        }, 
        "intervention": {
            "arm_group_label": [
                "ISIS-SMNRx Dose level 1", 
                "ISIS-SMNRx:  Dose level 2"
            ], 
            "description": "Single intrathecal injection for each dose", 
            "intervention_name": "ISIS-SMNRx", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Spinal Muscular Atrophy", 
            "SMA", 
            "SMN", 
            "SMNRx", 
            "ISIS-SMNRx", 
            "ISIS 396443"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "spaulose@stanford.edu", 
                    "last_name": "Shirley Paulose, MBBS, MS", 
                    "phone": "650-724-3792"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Day, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dcook@nemours.org", 
                    "last_name": "Dawn Cook, RN,MSN,CCRC", 
                    "phone": "407-650-7156"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32827"
                    }, 
                    "name": "Nemours Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Richard Finkel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rc2836@columbia.edu", 
                    "last_name": "Rosangel Cruz, MA, BS", 
                    "phone": "212-305-1336"
                }, 
                "contact_backup": {
                    "email": "jdm2132@columbia.edu", 
                    "last_name": "Jonathan Marra, MA", 
                    "phone": "212-305-2461"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Claudia Chiriboga, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lynn.macmillan@sickkids.ca", 
                    "last_name": "Lynn MacMillan, RN", 
                    "phone": "416-813-7355"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }, 
                    "name": "The Hospital for Sick Children (SickKids)"
                }, 
                "investigator": {
                    "last_name": "Jiri Vajsar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy", 
        "other_outcome": {
            "description": "- The observed CSF drug concentration", 
            "measure": "CSF Pharmacokinetics (See clarification.)", 
            "safety_issue": "No", 
            "time_frame": "CSF at Day 1, Day 15, and Day 85"
        }, 
        "overall_contact": {
            "email": "patients@isisph.com", 
            "last_name": "Isis Pharmaceuticals, Inc.", 
            "phone": "1-800-679-4747"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Patricipants will be followed for the duration of the study; an expected 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the maximal observed plasma drug concentration (Cmax)\nthe time to reach Cmax in plasma (Tmax)\nthe area under the plasma concentrations time curve from the time of the intrathecal dose to the last collected sample (20 hours after dosing)", 
            "measure": "Plasma Pharmacokinetics (See clarification.)", 
            "safety_issue": "No", 
            "time_frame": "Plasma at 1, 2, 4 and 24 hours after dosing"
        }, 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}